Envoy Medical FY23 EPS $(2.38) Down From $(1.57) YoY, Revenue $316K Up From $237K YoY
Portfolio Pulse from Benzinga Newsdesk
Envoy Medical reported a FY23 EPS of $(2.38), a decrease from $(1.57) YoY, while revenue increased to $316K from $237K YoY. Cash and cash equivalents stood at approximately $4.2 million as of December 31, 2023.
April 02, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Envoy Medical's FY23 report shows a decrease in EPS to $(2.38) from $(1.57) YoY and an increase in revenue to $316K from $237K YoY. Cash and cash equivalents are at $4.2 million.
The mixed financial results with a decrease in EPS but an increase in revenue suggest a neutral short-term impact on COCH's stock price. The increase in cash reserves indicates financial stability, which could counterbalance the negative EPS performance.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50